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We have investigated the existence, molecular compo-
sition, and benzodiazepine binding properties of native
cortical a1-a3 g-aminobutyric acidA (GABAA) receptors
using subunit-specific antibodies.
The co-existence of a1 and a3 subunits in native
GABAA receptors was demonstrated by immunoblot
analysis of the anti-a1- or anti-a3-immunopurified recep-
tors and by immunoprecipitation experiments of the
[3H]zolpidem binding activity. Furthermore, immu-
nodepletion experiments indicated that the a1-a3
GABAA receptors represented 54.7 6 5.0 and 23.6 6 3.3%
of the a3 and a1 populations, respectively. Therefore, a1
and a3 subunits are associated in the same native
GABAA receptor complex, but, on the other hand, these
a1-a3 GABAA receptors from the cortex constitute a
large proportion of the total a3 population and a rela-
tively minor component of the a1 population.
The pharmacological analysis of the a1- or a3-immu-
nopurified receptors demonstrated the presence of two
different benzodiazepine binding sites in each receptor
population with high (type I binding sites) and low (type
II binding sites) affinities for zolpidem and Cl 218,872.
These results indicate the existence of native GABAA
receptors possessing both a1 and a3 subunits, with a1
and a3 subunits expressing their characteristic benzodi-
azepine pharmacology.
The molecular characterization of the anti-a1-anti-a3
double-immunopurified receptors demonstrated the
presence of stoichiometric amounts of a1 and a3 sub-
units, associated with b2/3, and g2 subunits. The pharma-
cological analysis of a1-a3 GABAA receptors demon-
strated that, despite the fact that each a subunit
retained its benzodiazepine binding properties, the rel-
ative proportion between type I and II binding sites or
between 51- and 59–61-kDa [3H]Ro15-4513-photolabeled
peptides was 70:30. Therefore, the a1 subunit is pharma-
cologically predominant over the a3 subunit. These re-
sults indicate the existence of active and nonactive a
subunits in the native a1-a3 GABAA receptors from rat
cortex.
The neuropharmacological effects of benzodiazepines are me-
diated by the benzodiazepine (v) binding sites associated with
the GABAA
1 receptor complex (for reviews, see Refs. 1 and 2).
Based on their affinity for different drugs, two different benzo-
diazepine binding sites have been identified in the central
nervous system. Type I (benzodiazepine receptor 1, v1) displays
high affinity for CL 218,872 (2), b-carboline derivates (3), and
the imidazopyridine zolpidem (4, 5). Type II (benzodiazepine
receptor 2, v2) displays low affinity for these compounds. A
third benzodiazepine binding site with very low affinity for
zolpidem (type IIL, v5) has also been identified in isolated rat
brain membranes (6) and sections (7).
Molecular cloning experiments have demonstrated the exist-
ence of five different families of subunits that are components
of the GABAA receptor complex. Most of these families com-
prise several isoforms: a1–a6, b1–b3, g1–g3, d, and r1 and r2 (for
reviews, see Refs. 8 and 9). A minimum of a, b, and g subunits
should be co-expressed in transfected cells to resemble all the
pharmacological properties of native GABAA receptors (10). On
the other hand, the presence of different a subunits determines
the affinity of the different benzodiazepine binding sites. In
this sense, the a1-b1–b3-g2 combination confers type I pharma-
cology to the recombinant GABAA receptor (i.e. high affinity
for, among others, zolpidem and Cl 218,872) (11). Type II prop-
erties are conferred by the presence of a2, a3, or a5 subunits
(11, 12).
Several approaches have been taken to identify which sub-
units co-exist in the native GABAA receptor complex. However,
the subunit composition of the different native GABAA receptor
complexes remains unsolved. Immunoprecipitations or immu-
noaffinity purifications using anti-a subunit antibodies (anti-
a1, -a2, -a3, -a5, and -a6 subunits) indicated that a significant
proportion of native receptors are made by the association of
two different a subunits (such as a1a2, a1a3, a1a5, or a1a6)
(13–17) in a single receptor complex. However, other authors
have indicated the absence of association between different a
subunits (18, 19). On the other hand, the pharmacological
properties of these GABAA receptors are also unknown.
In the present article we have addressed these questions by
determining the molecular and pharmacological properties of
the immunopurified receptors using subunit-specific antibodies
to the major a subunits expressed in the rat cerebral cortex, the
a1 and a3 subunits.
EXPERIMENTAL PROCEDURES
Materials—[3H]Zolpidem (58.0 Ci/mmol), [3H]flumazenil (75.2 Ci/
mmol), [3H]Ro15-4513 (24.1 Ci/mmol), and [3H]flunitrazepam (84.0 Ci/* This work was supported by grant PB93–0739 from Direccion Gen-
eral de Investigacion Cientifica y Tecnica. The costs of publication of
this article were defrayed in part by the payment of page charges. This
article must therefore be hereby marked “advertisement” in accordance
with 18 U.S.C. Section 1734 solely to indicate this fact.
¶ To whom correspondence should be addressed. Tel.: 34-5-455-6754;
Fax: 34-5-423-3765.
1 The abbreviations used are: GABAA, g-aminobutyric acidA; PBS,
phosphate-buffered saline; FMZ, flumazenil; FNZ, flunitrazepam; mAb,
monoclonal antibody; CHAPS, 3-[(3-cholamidopropyl)dimethylammo-
nio]-1-propanesulfonic acid.
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mmol) were from DuPont NEN. Zolpidem was synthesized in the pre-
clinical research department of Synthe´labo Recherche. Cl 218,872 was
from Cyanamid. All other benzodiazepines were from Hoffmann-La
Roche.
Antibody Preparation—Peptides NH3-a3 (amino acids 1–10, pyroglu-
tamyl-GESRRQEPG) and COO2-a1 (amino acids 419–428, PQLKAPT-
PHQ) were synthesized and coupled to keyhole limpet hemocyanin, via
an extra tyrosine located at the COOH or NH2 terminus of a3 or a1
peptides, by Neosystem SA (Strasbourg, France). For immunizations,
rabbits (New Zealand White) were subcutaneously injected with 200 mg
of coupled peptide emulsified (1:2) in Freund’s complete adjuvant fol-
lowed 20 days later by a booster injection of conjugate with incomplete
adjuvant (1:1). Rabbits were then boosted every 2–3 weeks. The ani-
mals were bled 10 days after each booster injection. Development of an
immune response was followed by immunoprecipitation of the solubi-
lized receptor.
The antibodies were purified through peptide affinity columns. The
a3 and a1 peptides were coupled to adipic acid dihydrazide-agarose
(sigma) or CNBr-activated Sepharose 4B (Pharmacia Biotech), respec-
tively, as recommended by the manufacturer. Two ml of anti-a3 or
anti-a1 antisera (diluted 1/5 in PBS) were recirculated, overnight at
4 °C, in the corresponding 1-ml peptide column. After washing with 150
ml of PBS, the antibodies were eluted with 50 mM glycine-HCl, pH 2.3,
and the fractions (0.5 ml) were neutralized by 1 M Tris, pooled and
dialyzed in 1 liter of PBS (overnight at 4 °C).
Other antibodies used in this work were the mAb 63-3G1 and anti-g2
and -g3 antibodies. These two polyclonal antibodies were produced
using peptides from 2–10 or 1–15 amino acids of the NH3
1 terminus of
the g2 and g3 subunits, respectively (to be published elsewhere).
For immunoblots, the purified antibodies were labeled with digoxi-
genin as recommended by the manufacturer (Boehringer Mannheim).
The digoxigenin incorporated into anti-a1 or anti-a3 antibodies was
determined by enzyme-linked immunosorbent assay or dot blot. Both
antibodies displayed a similar activity (not shown).
Membrane Preparation and Receptor Solubilization—Membranes
from a 3-month-old Wistar rat cerebral cortex were prepared as de-
scribed elsewhere (6, 20) in presence of protease inhibitors: 1 mM EDTA,
1 mM EGTA, 1 mM dithiothreitol, 1 mM benzamidine, 50 mg/ml trypsin
inhibitor type II-S, and 50 mg/ml bacitracin.
The GABAA receptor was solubilized at 4 mg of protein/ml at 4 °C for
60 min with 0.5% (w/v) sodium deoxycholate, 0.5% (w/v) CHAPS, 140
mM NaCl, and 10 mM Tris-HCl, pH 7.5 (solubilization buffer), contain-
ing the same protease inhibitors as above. After centrifugation at
100,000 3 g for 60 min at 4 °C, the supernatant was collected. The
recovery of the benzodiazepine binding activity in the solubilized ma-
terial represented 80–90% of the 5 nM [3H]FMZ, 10 nM [3H]FNZ, or 5 nM
[3H]zolpidem binding activity found in membranes (also see Ref. 21).
Immunoprecipitation and Immunopurification—For immunoprecipi-
tation experiments, the different antisera were adsorbed to a suspen-
sion of protein A-Sepharose (10%, w/v, in solubilization buffer; also see
Refs. 20–22). Ten or 75 ml of anti-a1 or anti-a3 antibodies/assay were
incubated, for 2 h at 4 °C with agitation, with 50 ml of 10% protein
A-Sepharose in a final volume of 300 ml of solubilization buffer. The
IgG-protein A-Sepharose complexes were isolated by centrifugation,
washed three times with 1.4 ml of solubilization buffer, and used for
immunoprecipitation. On the other hand, preimmune sera was also
absorbed to protein A-Sepharose and used in control experiments.
The immunoaffinity columns were synthesized as described (15).
Briefly, 1–2 mg of each purified antibody were absorbed to 0.5 ml of
protein A-Sepharose. The IgG-protein A-Sepharose complex was
washed with 40 ml of PBS followed by 5 ml of 0.2 M triethylamine, pH
8.3. The column was then treated with 1.5 ml of 20 mM dimethylpime-
limidate in 0.2 M triethylamine, pH 8.3, for 30 min at room temperature.
After incubation, the medium was replaced by 1 ml of 0.2 M ethanola-
mine, pH 8.3, and incubated for 5 min. After coupling, the column was
packed and washed, at 10 ml/h, with: 1) 40 ml of PBS; 2) 2 ml of 140 mM
NaCl, 1 mM EDTA, 1 mM EGTA, and 50 mM sodium phosphate, pH 11.5;
and 3) 20 ml of PBS. The columns were pre-equilibrated with 10 ml of
solubilization buffer.
For immunopurification, the solubilized GABAA receptor (30 pmol of
[3H]FMZ binding activity) was recirculated (10 ml/h), overnight at 4 °C
through 0.5-ml columns. After absorption, the columns were washed (10
ml/h) with 20 ml of solubilization buffer. The retained material was
eluted at 10 ml/h with 3 ml of 140 mM NaCl, 1 mM EDTA, 1 mM EGTA,
0.5% sodium deoxycholate, 0.5% CHAPS, and 50 mM sodium phosphate,
pH 11.5. Fractions of 0.5 ml were collected and neutralized with 18 ml
of 1 M sodium phosphate. The GABAA receptor was identified by deter-
mining the binding activity of 5 nM [3H]FMZ. Positive fractions were
pooled, and 0.5 mg of BSA plus protease inhibitors was added. Alter-
natively, the immunoaffinity columns were eluted by treatment with
2% SDS in 10 mM Tris-HCl, pH 6.8, for 30 min at room temperature.
For immunopurification in series, the anti-a1-immunopurified recep-
tor was recirculating through 0.1-ml anti-a3 immunoaffinity columns.
After washing, the immunobeads were either aliquoted for binding
assays or eluted with SDS for immunoblot analysis of the retained
material (23).
The immunopurification was quantified by determining the binding
activity of [3H]FMZ (5 nM) in the solubilized receptor, the column
filtrate, and the final eluate.
The binding assays were done essentially as described previously
(20–22, 24, 25). Nonspecific binding was determined using 5 mM
clonazepam.
Pharmacological Properties of Immunopurified Receptors—Scat-
chard analysis of the immunopurified receptors was preformed as de-
scribed (6, 24, 26). Briefly, aliquots of the immunopurified receptors
were incubated in 50 mM Tris-HCl, pH 7.4, 0.05% sodium deoxycholate,
and 0.05% CHAPS (0.75-ml final volume) with six different concentra-
tions of [3H]FNZ (1–20 nM) or [3H]zolpidem (1–10 nM).
Displacement experiments were performed using 2 nM [3H]FNZ or
1.2 nM [3H]FMZ and 13 or 11 different concentrations of zolpidem
(ranging from 0.5 nM to 100 mM) or CL 218,872 (ranging from 5 nM to
100 mM), respectively, as described previously (6, 24).
Other Methods—The affinity purification of the bovine GABAA re-
ceptor complex and immunoblots has been described elsewhere (27).
Immunoblots were developed with luminol as recommended by the
manufacturer (Boehringer Mannheim). Proteins were determined by
the method of Lowry et al. (28). SDS-polyacrylamide gel electrophoresis
was done according to the method of Laemmli (29). Photoaffinity label-
ing and fluorography were performed as described (20).
Data Analysis—Scatchard transformations of the saturation curves
and the [3H]FNZ displacement curves were adjusted using LIGAND
(30), as described in detail elsewhere (6). The significance (p , 0.05) of
the fit of the displacement curves to a one or two binding site model was
determined by the F ratio test. The proportions of the different binding
sites were calculated from the “maximal density of binding sites” cor-
responding to each affinity, determined by LIGAND. Densitometric
analysis of both the immunoblots and the fluorographs was performed
as described (26).
RESULTS
Anti-a3 and -a1 Antibodies—Specific polyclonal antibodies
have been generated against peptides from the NH2-terminal
domain (amino acids 1–10) of the a3 subunit or the C-terminal
domain (amino acids 419–428) of a1 subunit of the GABAA
receptor complex. Both polyclonal antibodies immunoprecipi-
tated the native receptors solubilized from rat cortical mem-
branes in a dose-dependent manner (not shown). The maximal
immunoprecipitation (64 6 2 or 22 6 4% of the [3H]FMZ
binding) was achieved with 5 or 25 ml of anti-a1 or anti-a3
antibody, respectively. Similar results were obtained with 10
nM [3H]FNZ (not shown). A second round of incubation with
saturating amounts of either antibody immunoprecipitated
less than 5% of either binding activity (not shown).
The specificity of these polyclonal antibodies (Fig. 1) has
been tested by different criteria. 1) In dot blot experiments
using immobilized peptides, anti-a3 or anti-a1 antisera exclu-
sively recognized the peptide used as antigen (NH3
1-terminal
from a3 or COO
2-terminal from a1 subunits, respectively, Fig.
1A). Neither anti-a3 nor anti-a1 antisera immunoreacted with
peptides from similar regions of other a subunits (Fig. 1A). 2)
The immunoprecipitation of the native receptors was specifi-
cally inhibited by the peptide used as antigen but not by others
corresponding to similar NH3
1- or COO2-terminal regions of
other a subunits (Fig. 1, B and C). 3) In immunoblots using the
affinity-purified GABAA receptor (Fig. 1D) anti-a3 antiserum
immunoreacted with a faint band of Mr 59,000 (a3 subunit),
whereas anti-a1 strongly reacted with a single band of Mr
51,000 (a1 subunit). 4) In immunoblots using extracts from
cortical membranes (Fig. 1E) anti-a3 immunostained two
bands of Mr 59,000 and 61,000 (see Ref. 15) and, on the other
hand, anti-a1 recognized a Mr 51,000 peptide. A nonspecific
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band of 100 kDa was also observed in some experiments (also
see Fig. 2B). The mAb 62-3G1 (specific to b2 and b3,Mr 55,000–
57,000 peptides; Refs. 27 and 31) was included as a control. 5)
In the three brain regions studied (cortex, hippocampus, and
cerebellum), the percentage of immunoprecipitation by these
antibodies is consistent with the level of expression of a3 or a1
subunits, determined by in situ hybridization or immunopre-
cipitation (18, 19, 32–35). As expected, the anti-a1 antiserum
immunoprecipitated most of the [3H]FMZ binding activity from
the cerebellum (85.3 6 7.5%), followed by the cortex (71.0 6
5.3%) and hippocampus (52.2 6 2.0%). Anti-a3 antiserum im-
munoprecipitated a low proportion of receptors compared with
anti-a1. The maximal immunoprecipitation was obtained in the
cortex (25.8 6 4.7%), followed by the hippocampus (19.1 6
3.2%) and cerebellum (9.8 6 3.5%). In conclusion, by all these
criteria both antibodies are specific for their corresponding
subunits.
Association between a1 and a3 Subunits—To determine the
presence of a1 subunits, co-assembled with a3 subunits in the
same receptor complex, we first quantified the [3H]zolpidem
binding activity immunoprecipitated by anti-a3 antiserum.
[3H]Zolpidem binds with high affinity to a1 subunit-containing
GABAA receptors (type I benzodiazepine binding sites) (11, 12,
21, 22). Therefore, [3H]zolpidem (5 nM) binding activity was
used as a marker of the presence of a1 subunits in the immu-
noprecipitated receptor (also see Ref. 21). The quantitative
immunoprecipitation of [3H]zolpidem binding was tested by
two sequential incubations with anti-a1 or anti-a3 antibodies.
The second incubation yielded 3.3 6 2.8 and 3.8 6 1.7% of
immunoprecipitation for anti-a1 and -a3, respectively, indicat-
ing that the immunoprecipitation of the receptor was maximal.
As shown in Fig. 2A, anti-a1 and -a3 antibodies immunopre-
cipitated 90.0 6 5.4 and 26.9 6 3.6% of the [3H]zolpidem
binding activity, respectively. These results demonstrated that,
in native GABAA receptors, the high affinity [
3H]zolpidem (5
nM) binding sites (type I benzodiazepine binding sites) are
largely associated with the presence of an a1 subunit (also see
Refs. 21 and 22) and, importantly, that these sites can be
immunoprecipitated in association with a3 subunits.
To ascertain the co-assembling of a1 and a3 subunits in the
FIG. 1. Specificity of anti-a3 and anti-a1 antisera. A, different amounts of peptides from NH2 termini (amino acids 1–10) of a3, a1, or a5
subunits or COOH termini of a1 (amino acids 419–428), a3 (amino acids 459–465), or a5 (amino acids 424–433) were blotted and immunostained
with anti-a3 (1/1000 dilution) and anti-a1 (1/1000 dilution) antisera, respectively. B and C, solubilized receptor (0.1–0.2 pmol of [
3H]FMZ binding
activity) was immunoprecipitated with 0.5 or 7.5 ml of anti-a1 or anti-a3 antisera, respectively, in the presence of increasing concentrations of the
peptides specified above. B, COOH-terminal peptides a1 (f), a3 (l), and a5 (); C, NH2-terminal peptides a1 (f), a3 (l), and a5 (). No inhibition
was observed when anti-a1 or anti-a3 antisera were incubated in presence of NH2-terminal a1 or COOH-terminal a3 peptides, respectively (not
shown). Results are expressed as percentages from the [3H]FMZ binding activity immunoprecipitated in absence of peptide and are mean 6 S.D.
(bars) of three independent experiments. D, GABAA receptors purified from adult bovine cerebral cortex (1 mg/lane) were subjected to SDS-
polyacrylamide gel electrophoresis, blotted, and immunostained with anti-a3 (1/500 dilution) or anti-a1 (1/1000 dilution). Both antibodies show
reactivity with single peptide bands of 59 and 51 kDa for anti-a3 and anti-a1, respectively. E, cortical membranes (75 mg of protein/lane) were
processed as above and immunostained with 10 mg/ml of purified anti-a3 or anti-a1 antibodies. The mAb 62-3G1 (1/5 dilution), specific for b2 and
b3 subunits, was included as a reference. The molecular sizes of the subunits are 58 and 60 kDa (a3), 51 kDa (a1) and 55–57 kDa (b2 and b3).
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same receptor complex, the solubilized GABAA receptor was
purified by anti-a1 or anti-a3 immunoaffinity columns. The
results of the purification experiments are shown in Table I.
Both immunoaffinity columns retained the GABAA receptor
complex. The percentage of binding immunoabsorbed to the
columns was similar to that determined by immunoprecipita-
tion experiments. The anti-a1 immunoaffinity column was ef-
ficiently eluted at pH 11.5 (21.3 6 3.1% of the solubilized
receptors or 33.0 6 1.0% of the immunoabsorbed material).
However, no significant benzodiazepine binding could be eluted
from anti-a3 columns (0.7 6 0.3%). Other treatments, such as
low pH, did not improve the elution step (not shown). There-
fore, to analyze the immunopurified receptor, both immunoaf-
finity columns were eluted with SDS, and the purified material
was subjected to immunoblot analysis. As shown in Fig. 2B, the
presence of a3 subunits (59- and 61-kDa peptides) could be
detected in anti-a1-immunopurified receptors, and, on the
other hand, the a1 immunoreactivity (51-kDa peptide) was
identified in anti-a3-immunopurified receptors.
The co-purification of both a subunits was not due to cross-
reaction between the antibodies. As shown in Fig. 2C (lane 2),
the anti-a1 antibody produces absolutely no immunoreaction
products in Western blots of the anti-a3-immunopurified recep-
tors that have been immunodepleted of the a1 subunits. On the
other hand, the anti-a3 antibody immunoreacted with 59–61-
kDa peptides (Fig. 2C, lane 3), demonstrating the presence of
a3-containing GABAA receptors. Conversely, no immunoreac-
tion products were produced by the anti-a3 antibody using the
a3 immunodepleted and anti-a1-immunopurified receptor as an
antigen (Fig. 2C, lanes 5 and 6). Furthermore, in membrane
preparations of human embryonic kidney cells, transfected
with the a1-g2-b2 combination, the anti-a1 antibody immuno-
stained a single 51-kDa peptide, whereas no immunoreaction
products were detected using the anti-a3 antibody (not shown).
These results clearly demonstrate the absence of cross-reaction
between the antibodies and confirm the co-purification of both
a subunits in the same receptor complex.
It could be argued that the co-purification of two different a
subunits, such as a1 and a3, was due to interactions between
individual GABAA receptor complexes through cytoskeletal el-
ements (36) or, on the other hand, to the presence of anomalous
receptors (partially assembled receptors) due to the solubiliza-
tion of intracellular stores in our membrane preparations (37).
Additional control experiments were performed to test these
possibilities. Treatment of the cortical membranes, prior to
solubilization and purification, with 5 mg/ml demecolcine (a
tubulin-depolymerizing agent) or 10 mg/ml cytochalasin D (an
actin-depolymerizing agent) did not modify the percentage of
FIG. 2. Co-localization of a1 and a3 subunits in the same GABAA complex demonstrated by cumulative immunoprecipitation (A),
an immunoblot of the immunopurified receptors (B), and the absence of cross-reaction between the antibodies (C). A, the solubilized
receptors (1.0 pmol of [3H]FMZ binding activity) were immunoprecipitated by sequential incubation with 85 and 75 ml or 15 and 15 ml of anti-a3
or anti-a1 antibodies, respectively. The [
3H]zolpidem (5 nM) binding were determined in the pellets and in the last supernatant. The results are
expressed as percentages of the total specific binding for each ligand and are mean6 S.D. (bars) of six to eight experiments. B, the GABAA receptors
were immunopurified by anti-a1 (lanes 1 and 2) or anti-a3 (lanes 3 and 4) immunoaffinity columns. After washing, the immunoaffinity columns
were treated with SDS, and the eluted receptor was analyzed by immunoblot using 5 mg of purified anti-a1 (lanes 1 and 3) or anti-a3 (lanes 2 and
4) antibodies. C, the a1 or a3 subunits were immunodepleted from the solubilized receptor by three sequential incubations with anti-a1 (15 ml each)
and anti-a3 (75 ml each), respectively. The a1- or a3-immunodepleted receptors were immunopurified by anti-a3 (lanes 2 and 3) and anti-a1 (lanes
5 and 6) immunoaffinity columns. Lanes 1 and 4, anti-a1 and anti-a3 control immunopurifications, respectively. The eluted receptor was analyzed
by immunoblot using 5 mg of purified anti-a1 (lanes 1, 2, and 6) or anti-a3 (lanes 3–5) antibodies. For all immunoblots, the affinity-purified
antibodies were labeled with digoxigenin. Numbers on the left, Mr values of the immunostained bands.
TABLE I
Immunoaffinity purification of a1- and a3-containing GABAA
receptors from rat cerebral cortex
The solubilized GABAA receptor was purified on 0.5-ml immunoaf-
finity columns, as described under “Experimental Procedures.” The
[3H]FMZ (5 nM) binding activity was determined in each fraction. The
results are mean 6 S.D. of at least three independent experiments.
[3H]FMZ binding
Anti-a1 column Anti-a3 column
pmol % pmol %
Solubilized receptor 30 6 6 100 30 6 4 100
Bound 19.3 6 0.5 64.3 6 1.5 6.1 6 1.5 20.5 6 4.9
pH 11.5 elution 6.3 6 0.9 21.3 6 3.1 0.2 6 0.1 0.7 6 0.3
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[3H]zolpidem binding activity immunoabsorbed to anti-a3 im-
munobeads (26.3 6 1.5 versus 32.5 6 5.4 and 31.2 6 3.7%, n 5
3, for control and demecolcine- or cytochalasin D-treated mem-
branes, respectively). Furthermore, after treatment with either
drug, two [3H]Ro15-4513 photoaffinity-labeled peptides of 51
and 59–61 kDa were immunopurified by anti-a3 columns (not
shown). On the other hand, results similar to those shown in
Fig. 2A were obtained using purified synaptic membranes as
starting material (not shown).
The co-assembling of a1 and a3 in the same receptor complex
also could be due to redistribution of subunits during solubili-
zation. This possibility was tested by determining the immu-
noprecipitation by anti-a3 of the diazepam-insensitive [
3H]Ro
15-4513 binding sites in solubilized receptors from cerebellar
membranes or from the mixture (1:1) of cerebellar plus cortical
membranes. The diazepam-insensitive binding sites are asso-
ciated with the presence of a6 subunits (38, 39), and this sub-
unit is not expressed in the cortex (32, 33, 39). The immuno-
precipitation of diazepam-insensitive [3H]Ro15-4513 binding
activity by anti-a3 was very low and similar in both solubilized
preparations, pure cerebellar membranes, and a mixture of
cerebellar and cortical membranes (0.01 6 0.01 and 0.01 6 0.01
pmol, n 5 2, respectively), thus indicating that no apparent
subunit redistribution takes place due to solubilization
procedures.
The association between both a subunits was quantified by
immunodepletion experiments. In these experiments, a partic-
ular a subunit was depleted by two sequential immunoprecipi-
tations with the specific antiserum. After depletion, the re-
maining GABAA receptor complex was immunoprecipitated by
the other a subunit. As shown in Table II, depletion of a1
subunits produced a significant decrease in the [3H]FMZ bind-
ing activity immunoprecipitated by anti-a3 antiserum (0.21 6
0.04 versus 0.10 6 0.01 pmol, respectively). Thus, 54.7 6 5.0%
of the benzodiazepine binding activity immunoprecipitated by
anti-a3 was depleted by preincubation with the anti-a1 anti-
serum. On the other hand, most of the [3H]zolpidem immuno-
precipitated by the anti-a3 antiserum was depleted by prein-
cubation with the anti-a1 antibody (89.0 6 7.8%; 0.05 6 0.01
versus 0.005 6 0.004 pmol). These results indicated that most,
if not all, of the high affinity binding sites immunoprecipitated
by the anti-a3 antiserum were due to the presence of an a1
subunit.
Reciprocally, depletion of a3 subunits also affected the im-
munoprecipitation by the anti-a1 antiserum. As shown in Table
II, depletion of a3 subunits produced a decrease in the [
3H]FMZ
or [3H]zolpidem binding activity immunoprecipitated by an-
ti-a1 (0.70 6 0.05 or 0.24 6 0.01 pmol versus 0.54 6 0.03 or
0.17 6 0.01 pmol for [3H]FMZ and [3H]zolpidem, respectively).
Thus, 20–25% of the a1 population is associated with an a3
subunit in the same receptor complex.
As mentioned above, the second immunoprecipitation with
either antibody or for either binding site yielded a residual
3–4% of immunoprecipitation. Therefore, after two rounds of
immunoprecipitation, a particular a subunit should be com-
pletely depleted from the solubilized material. However, no
attempts were made to detect the depleted subunit remaining
in the supernatants. We are aware that some residual amounts
of the depleted subunit could persist in the solubilized recep-
tor. Therefore, these results could be, in some extent,
underestimated.
Pharmacological Properties of Anti-a1- or Anti-a3-immuno-
purified Receptors from Rat Cortex—The pharmacological prop-
erties of the anti-a1- or anti-a3-immunopurified receptors were
determined by [3H]zolpidem and [3H]FNZ saturation studies
and by displacement experiments using aliquots from the im-
munoaffinity columns.
As shown in Table III, in receptors immunopurified by an-
ti-a1 or anti-a3, the Scatchard transformation of saturation
experiments with [3H]zolpidem or [3H]FNZ were linear, with
Hill slopes close to unity, indicating the presence of a single
high affinity binding population for each ligand. Affinities (KD)
for [3H]zolpidem or [3H]FNZ were similar in both anti-a3 or
anti-a1-immunopurified receptors and very close to KD values
obtained in crude cortical rat membranes for type I or total
benzodiazepine binding sites (4, 6, 24, 40).
The presence of two pharmacologically distinct receptors in
the anti-a3 and anti-a1-immunopurified receptors also has
been tested by displacement studies of [3H]FNZ by type I-spe-
cific ligands (such as zolpidem or Cl 218,872). In both anti-a1-
and anti-a3-immunopurified receptors and for both zolpidem
and Cl 218,872, the Hill slope of the displacement curves was
lower than unity (Table III), indicating the existence of a het-
erogeneous population of binding sites. Furthermore, in every
case, displacement curves were better fitted (based on the extra
sum of squares using the program LIGAND, three of three
experiments; p , 0.05) to a two binding site model with high
(Ki, 5–8 and 40–70 nM for zolpidem and Cl 218,872, respec-
tively) and low (Ki, 390–430 nM and 2–3.5 mM for zolpidem or
CL 218,872, respectively) affinity (Table III). In contrast, diaz-
epam displaced the [3H]FNZ binding immunopurified by the
anti-a3 antibody, with a Hill coefficient of 1.2 and a single high
affinity site (Ki, 7.1 nM). It is interesting that all the calculated
Ki values were very similar to those determined in crude cor-
tical membrane preparations for type I and II benzodiazepine
receptors (6, 24).
Immunopurification and Pharmacological Properties of a3-a1
GABAA Receptors—The association of a3 and a1 subunits and
the pharmacological properties of the a3-a1 GABAA receptors
were further tested by using sequential immunopurification
(see Refs. 14 and 16). The GABAA receptor was first immuno-
purified by anti-a1 immunoaffinity columns, and the eluted
TABLE II
Quantification of the association between a1 and a3 subunits by immunodepletion experiments
The immunodepletion of a1 or a3 subunits was done by two sequential incubations of the solubilized receptor (1 pmol of [
3H]FMZ binding sites)
with either anti-a1 (10 1 10 ml) and anti-a3 (75 1 75 ml) antibodies, respectively. The remaining receptor was immunoprecipitated by incubation
with 75 or 10 ml of anti-a3 and -a1 antisera, respectively. The binding activity was determined in pellets and supernatants. The results are
expressed as pmol of [3H]FMZ (5 nM) or [3H]zolpidem (5 nM) specific binding activity immunoprecipitated in each condition. The percentage of
depletion was calculated from the specific binding activity immunoprecipitated before and after depletion. Data are mean 6 S.D. of three to six
independent experiments.
Subunit
depleted
Subunit
immunoprecipitated
Specific binding activity
[3H]FMZ [3H]zolpidem
pmol
immunoprecipitated
% of depletion pmol
immunoprecipitated
% of depletion
a3 0.21 6 0.04 0.05 6 0.01
a1 a3 0.10 6 0.01 54.7 6 5.0 0.005 6 0.004 89.0 6 7.8
a1 0.70 6 0.05 0.24 6 0.01
a3 a1 0.54 6 0.03 23.6 6 3.3 0.17 6 0.01 26.0 6 5.0
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material was absorbed to anti-a3 immunoaffinity columns. As
was mentioned before (see Table I), no significant elution from
the anti-a3 immunoaffinity columns could be achieved. There-
fore, the GABAA receptor retained by the anti-a3 columns was
analyzed by binding assays using aliquots of the anti-a3 immu-
nobeads (see Ref. 23) or by immunoblots of the SDS-eluted
receptors.
We first quantified the presence of a3 subunits in the anti-
a1-immunopurified receptors by testing the percentage of
[3H]FMZ and [3H]zolpidem binding activity immunoabsorbed
to anti-a3 columns. Anti-a1 immunobeads were used as control.
As shown in Fig. 3A, the second anti-a1 columns immunoab-
sorbed 90–95% of the previously anti-a1-immunopurified re-
ceptors, whereas anti-a3 columns immunoabsorbed 20–25% of
either [3H]FMZ and [3H]zolpidem binding sites previously im-
munopurified by anti-a1 columns. This indicated that 20–25%
of the a1 population also contained an a3 subunit. These values
agree with those calculated by depletion experiments (see
Table II).
The presence of both a subunits, together with b2/3 and g2
subunits, in the a1- and a3-immunopurified receptors was dem-
onstrated by immunoblots. As shown in Fig. 3B, after sequen-
tial anti-a1 and anti-a3 immunopurifications, the anti-a1 anti-
body immunoreacted with a single 51-kDa band, whereas the
anti-a3 antibody immunostained a doublet of 59 and 61 kDa.
The mAb 62-3G1 and anti-g2 antibodies immunostained pep-
tides of 55–57 and 47–49 kDa, respectively. The presence of g3
was not detected (not shown). These results demonstrated that
both a1 and a3 subunits, b2/3 and g2 are co-assembled in the
same GABAA receptor complex.
The stoichiometry between both a subunits was estimated by
densitometric analysis of semiquantitative immunoblots (Fig.
4; also see Ref. 16). For these experiments, a fixed amount of
receptor was immunoblotted and incubated with increasing
concentrations of both antibodies in combination. After 4 h of
incubation, the medium was aspirated and replaced by a new
batch of antibodies. The immunoreaction products were quan-
tified by densitometry. As shown in Fig. 4, A and B, at satu-
rating concentrations, both antibodies yielded similar amounts
of immunoreaction products. Thus, these results indicated a
stoichiometry of approximately 1:1 (a3/a1 ratio, 1.1 6 0.1, n 5
2; Fig. 4B).
Finally, we have tested the pharmacological properties of the
a1- and a3-immunopurified GABAA receptors by displacement
experiments with Cl 218,872 or zolpidem and also by [3H]Ro15-
4513 photoaffintiy labeling experiments of the double-immuno-
purified receptor. The results are shown in Table IV and Fig. 5.
The displacement experiments of both [3H]FNZ or [3H]FMZ
(not shown) binding activity by both zolpidem or Cl 218,872
demonstrated the presence of two different binding sites with
high (type I) and low (type II) affinities. The proportion be-
tween both binding sites, calculated from displacement ex-
FIG. 3. Binding activity and molecular composition of the a1-a3 GABAA receptor from rat cortex. A, the anti-a1-immunopurified
GABAA receptors were immunoabsorbed to anti-a1 (M) or anti-a3 (p) immunobeads, and the [
3H]FMZ (5 nM) or [3H]zolpidem (5 nM) binding activity
was quantified in pellets and supernatants. The results, expressed as percentages of binding activity retained by the columns, are mean 6 S.D.
(bars) of three experiments. B, the GABAA receptors were immunopurified by anti-a1 and anti-a3 columns in series. The SDS-eluted material was
blotted and incubated with 5 mg of purified anti-a1 (lane 1) or anti-a3 (lane 2) antibodies, a 1/5 dilution of the mAb 62-3G1 (specific for b2 and b3
subunits; lane 3), or 5 mg of purified anti-g2 antibody (lane 4). Numbers on the left, Mr values of the immunostained bands.
TABLE III
Pharmacological characterization of the anti-a1 and anti-a3 immunopurified GABAA receptors from rat cortex
The solubilized receptor was immunoabsorbed to anti-a3 or anti-a1 affinity columns. For saturation or displacement experiments, aliquots of the
anti-a1 or anti-a3 immunobeads (0.4–0.6 pmol of [
3H]FNZ binding activity/tube) were used. Saturation experiments were done by incubating the
immunobeads with five or six different concentrations of [3H]FNZ (1–20 nM) or [3H]zolpidem (1–10 nM). The Scatchard transformation of the data
was performed by LIGAND. Displacement experiments were performed by determining the binding activity of 2 nM [3H]FNZ and 13 or 10 different
concentrations of zolpidem (ranging from 5 3 10210–1024 M) or CL 218,872 (ranging from 5 3 1029–1024 M), respectively. Displacement curves were
fit (LIGAND) to a one or two binding site model. Results, mean 6 S.D. of three experiments, are expressed in nM.
Immunoaffinity column Ligand
Scatchard or displacement experiments
nH
One binding
site, KD or Ki
Two binding sites
Ki Ki P(2S/1S)
Anti-a3 [
3H]FNZ 0.94 6 0.02 3.5 6 2.0
[3H]Zolpidem 0.96 6 0.03 14.8 6 2.3
Zolpidem 0.57 6 0.05 204 6 68 8.0 6 7.1 392 6 100 0.02
Cl 218,872 0.55 6 0.02 1,525 6 220 67.5 6 9.0 3,460 6 900 0.03
Anti-a1 [
3H]FNZ 0.94 6 0.02 6.2 6 1.9
[3H]Zolpidem 0.99 6 0.01 13.3 6 2.8
Zolpidem 0.60 6 0.03 88 6 20 5.0 6 4.9 424 6 71 0.01
Cl 218,872 0.58 6 0.03 310 6 84 39.6 6 2.4 1,840 6 360 0.03
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periments, was 70:30 for high and low affinity, respectively
(see Table IV).
On the other hand, [3H]Ro15-4513 (5 nM) photoaffinity-label-
ing experiments demonstrated the presence of two different
labeled peptides of 51 and 59–61 kDa in the a1-a3 GABAA
receptors (Fig. 5, lane 3). The molecular masses of these pho-
toaffinity-labeled peptides corresponded to the major bands
present in anti-a3-immunopurified (Fig. 5, lane 2) and anti-a1-
immunopurified (Fig. 5, lane 1) receptors. The proportion be-
tween 51- and 59–61-kDa bands, determined by densitometric
analysis of the fluorographs, was 70:30 (Fig. 5B). The propor-
tion between both photolabeled peptides, in the double a1- and
a3-immunopurified receptors, was further analyzed at two dif-
ferent degrees of saturation of the benzodiazepine binding
sites. For these experiments, the membranes were photola-
beled with 10 or 20 nM [3H]Ro15-4513 (Fig. 5, lanes 4 and 5). As
shown in Fig. 5B, the proportion between the 51- and 59–61-
kDa photolabeled peptides was identical at all three [3H]Ro15-
4513 concentrations.
DISCUSSION
The molecular composition of native GABAA receptors is
unknown. Evidence is accumulating for the existence of differ-
ent a subunit combinations (such as a1a3, a1a2, a1a5, and a1a6)
co-assembled in single native GABAA receptor complexes. How-
ever, other studies also indicated the absence of co-existence
between different a subtypes (18, 19). On the other hand, it is
currently accepted that the benzodiazepine binding properties
of the GABAA receptors are mainly determined by the a sub-
units (10, 11, 12). Therefore, if two different a subunit subtypes
are co-assembled in a single GABAA receptor, two pharmaco-
logically different benzodiazepine binding sites could co-exist in
a single complex. In the present article we have investigated
the possible existence and the pharmacological properties of
native a1-a3 GABAA receptors from the rat cortex.
The presence of a1 and a3 subunits in the same GABAA
receptor complex was demonstrated by immunoprecipitation
and immunopurification experiments. It has been described
that, in transfected GABAA receptors, the high affinity binding
sites for zolpidem (type I benzodiazepine binding sites) are
determined by the presence of a1 subunits. Other a subtypes
(such as a2, a3, and a5) confer low affinity for this ligand (type
II benzodiazepine receptors) (11, 12). Therefore, the association
of an a1 with other a subunits could be estimated by immuno-
precipitation of the [3H]zolpidem binding activity. Our immu-
noprecipitation experiments (Fig. 2A and Refs. 21 and 22)
demonstrate that most, if not all (90.0 6 5.4%), of the high
affinity binding sites for zolpidem are due to the presence of an
a1 subunit in the GABAA receptor. Importantly, 25–30% of
these [3H]zolpidem binding sites were immunoprecipitated by
anti-a3 antibody, thus suggesting an a1-a3 association. Consis-
tently, immunodepletion of the a1 subunits suppress the im-
munoprecipitation of [3H]zolpidem binding by the anti-a3
antibody (Table II). Thus, a1 binding properties could be im-
munoprecipitated in association with a3 subunits, suggesting
the presence of both a1 and a3 subunits in the same receptor
complex.
The association between both subunits was confirmed by
immunopurification experiments. The immunoblot analysis of
the anti-a1- or anti-a3-immunopurified receptors (Fig. 2B) re-
vealed the presence of a3 immunoreaction product in the anti-
FIG. 4. Stoichiometry of the a1 and a3 subunits in the a1-a3-immunopurified GABAA receptors from rat cortex. A, a fixed amount of
the double-immunopurified GABAA receptor was blotted and incubated with increasing amounts (0.2, 2, 8, and 16 mg/ml each antibody) of purified
anti-a1 and anti-a3 antibodies in combination. B, densitometric analysis of the immunoblot shown in A. As a control of the staining protocol, a fixed
amount of purified IgG (2 mg) was blotted, stained with the second antibody, and analyzed by densitometry. This experiment was repeated twice
with similar results.
TABLE IV
Pharmacological properties of the a1- and a3 GABAA receptors purified by anti-a1 and anti-a3 immunoaffinity columns in series
The solubilized GABAA receptor (30 pmol of [
3H]FMZ binding) was immunopurified by anti-a1 immunoaffinity column. The eluted receptor was
immunoabsorbed to anti-a3 columns. After washing, the anti-a3 immunobeads were aliquoted (0.2 pmol of [
3H]FMZ binding/assay). Displacement
experiments were performed as described in Table III. The proportion between the different binding sites, given in parentheses, was calculated
from the maximal density of binding sites determined by LIGAND. The results are mean 6 S.D. of two independent experiments.
Ligand
Displacement of [3H]FNZ binding
nH One binding site, Ki
Two binding sites
p(2S/1S)
Ki Ki
nM nM nM
Cl 218,872 0.69 6 0.01 173.5 6 68 46.3 6 4.2 950 6 200 ,0.004
(69.5 6 2.5%) (30.5 6 2.5%)
Zolpidem 0.73 6 0.10 56.2 6 6.8 13.0 6 1.8 190 6 89 ,0.03
(69.0 6 8.5%) (31.0 6 8.5%)
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a1-immunopurified receptors and, reciprocally, the presence of
a1 in anti-a3-immunopurified receptors. Furthermore, the as-
sociation between both a subunits was not due to interactions
with cytoskeletal elements. Taken together, these results dem-
onstrated the existence of a1-a3 GABAA receptors from the rat
cortex. Immunodepletion experiments indicated that the a1-a3
GABAA receptors constituted a relatively minor proportion of
the total a1-containing GABAA receptors (20–25% of this pop-
ulation) but 50–55% of the a3 containing GABAA receptors.
Thus, and in partial agreement with previous reports (13–15),
the association between two different a subunits represents a
minor population from the total a1-containing receptors but a
high proportion of other a subunits, such as a3.
The presence of different a subtypes, in combination with
b1–b3 and g2 subunits, determines the benzodiazepine binding
properties of recombinant GABAA receptors (10, 11, 12). As
mentioned above, the a1 subunit confers type I benzodiazepine
binding properties (high affinity for zolpidem and Cl 218,872),
whereas the a3 subunit confers type II binding properties (low
affinity for these ligands). Therefore, if two different a sub-
units, such as a1 and a3, are co-assembled in the same receptor
complex, and both a1 and a3 subunits are pharmacologically
active, two different benzodiazepine binding subtypes should
be discriminated in either anti-a1- and anti-a3-immunopurified
receptors. As shown in Table III, in anti-a1- and anti-a3-immu-
nopurified receptors, two different binding sites were identi-
fied. The affinities for zolpidem (determined by Scatchard and
displacement experiments) or Cl 218,872 (determined by dis-
placement experiments) were similar in both immunopurified
receptors and similar to those reported for type I and II ben-
zodiazepine binding sites in cortical membranes (6, 7). Further-
more, the affinities for both ligands corresponded to those
reported for recombinant receptors containing a1 subunits
(high affinity binding sites) and a3 subunits (low affinity bind-
ing sites) (11, 12). In consequence, these results suggest the
presence of benzodiazepine binding sites in both a1 and a3
subunits co-assembled in a single GABAA receptor complex
(also see Ref. 17).
To discern whether both a1 and a3 subunits, co-assembled in
a single complex, display benzodiazepine binding activity, the
GABAA receptor was immunopurified by anti-a1 and anti-a3
affinity columns in series; therefore, the whole population of
the isolated GABAA receptors should contain two different a
subunits. It is noteworthy that anti-a3 immunoaffinity columns
retained 20–25% of the a1-immunopurified GABAA receptors,
corroborating the proportion of a1 to a3 GABAA receptors cal-
culated by depletion experiments (compare Fig. 3A and Table
II). Immunoblot analysis (Fig. 3B) indicates that a1 and a3
subunits are mainly associated with b2/3 and g2 in the same
receptor complex, consistent with previous experiments (21,
22). The b1 subunits are a relatively minor component of the
receptor (41), and, on the other hand, it has been demonstrated
that g1 is not associated with g2-containing GABAA receptors
(42). Thus, we propose a molecular composition of a1, a3, b2/3
and g2 for these native GABAA receptor complexes from rat
cortex.
A relevant question to ascertain the pharmacological activity
of the a subunits, co-assembled in a single native GABAA
receptor, is the stoichiometry between both subunits in the
complex. Thus, we have estimated the stoichiometry between
both a subunits by quantifying the immunoreaction products of
anti-a1 and anti-a3 antibodies in immunoblots. We are aware
that immunoblots are only semiquantitative. However, within
the limitations of the technique, the results (Fig. 4) indicated
the presence of stoichiometric amounts of each a subunit (ratio
1:1; also see Ref. 16 for discussion). The stoichiometry of g2, b2,
and b3 subunits was not determined.
If both a subunits display benzodiazepine binding sites, the
double-immunopurified receptors should display type I and II
binding properties in similar proportions, and two peptides
should be photoaffinity labeled by [3H]Ro15-4513 to a similar
extent. Indeed, the pharmacological analysis of the a1-a3
GABAA receptors indicated the presence of two different ben-
zodiazepine binding sites. Both Cl 218,872 and zolpidem dis-
criminated between two different binding sites with high (type
I) and low affinities (type II). The calculated Ki values for either
ligand were similar to those of immunopurified a1 or a3 recep-
tors (compare Tables III and IV) and to cerebral membranes (6,
7). However, the proportion between both binding sites (70:30
for high and low affinity, respectively) demonstrates that the a1
subunits are predominantly active over the a3 subunits. It
could be argued that the different proportions between both
binding sites, determined by displacement experiments, is due
to differences in the KD values of a1 and a3 subunits for the
FIG. 5. Fluorography (A) and desitometric analysis (B) of the [3H]Ro15-4513-photolabeled and immunopurified GABAA receptor
from rat cortex. A, the cortical membranes were photoaffinity labeled with 5, 10, and 20 nM [3H]Ro15-4513, solubilized, and immunopurified by
anti-a1, anti-a3, or anti-a1 and anti-a3 immunoaffinity columns in series. The fluorographs were exposed for three different periods. Fluorographs
shown were exposed for 20 days (anti-a3) or 10 days (anti-a1 or anti-a1 and anti-a3). B, densitometric analysis of the photolabeled peptides at 5,
10, and 20 nM [3H]Ro15-4513, immunopurified by anti-a1 and anti-a3 columns in series. The data are mean 6 S.D. (bars) of two independent
experiments.
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3H-labeled ligand ([3H]FNZ or [3H]FMZ). However, these re-
sults were confirmed by [3H]Ro15-4513 photoaffinity-labeling
experiments at three different degrees of saturation. As ex-
pected, in the double-immunopurified receptors, two photola-
beled peptides of 51 kDa (corresponding to a1 subunits) and
59–61 kDa (a3 subunits) were identified. However, despite the
fact that both a subunits are assembled in stoichiometric
amounts in the same receptor complex, the proportion between
both photolabeled peptides (at all three concentrations) was
70:30 for 51 and 59–61 kDa, respectively (Fig. 5). Thus, a1
subunits are pharmacologically predominant over the a3 sub-
units. It should be noted that [3H]Ro15-4513 photolabeled
most, if not all, the benzodiazepine binding sites from cerebral
membranes (90% in this work; also see Ref. 43).
Our data could be explained by the existence of at least two
pharmacologically different populations of a1-a3 GABAA recep-
tors (see Fig. 6 for a model). As shown in Fig. 6A, 70% of the
a1-a3 GABAA receptors may be assembled by a functional a1
subunit associated with an inactive a3 subunit. The remaining
30% of the population may be constituted by a functional a3
subunit associated with inactive a1 subunits. Nevertheless, we
cannot completely exclude the existence of a1-a3 GABAA recep-
tors containing two benzodiazepine binding sites (Fig. 6B). In
such a model, in which two functional a1 and a3 subunits are
co-localized in the same receptor complex, 60% of the benzodi-
azepine binding sites should be conferred by GABAA receptors
containing two functional a subunits and 30% by functional a1
subunits associated with inactive a3 subunits. Our results do
not allow discrimination between these two models.
The presence or absence of active benzodiazepine binding
sites could be determined by the distribution of the a and g2
subunits in the pentameric GABAA receptor complex (10, 44). It
has been proposed that both a and g2 subunits are implicated
in the benzodiazepine binding sites (44, 45), and, on the other
hand, the GABAA receptors may contain two a subunits, two b
subunits, and a single g2 subunit (46, 47). Thus, the predomi-
nance of a1 pharmacology (type I benzodiazepine binding sites
or the 51-kDa photolabeled peptides) could be interpreted by
the presence of a single g2 subunit properly associated with the
a1 subunit in the a1-a3 GABAA receptor complex (Fig. 6A). In
these receptors, the a3 subunits should lack the benzodiazepine
binding sites (see Fig. 6). On the other hand, two different g2
subunits could also co-exist in the same receptor complex (46,
48). If this is the case, both a subunits could display benzodi-
azepine binding properties (Fig. 6B).
The physiological significance of GABAA receptors contain-
ing two different a subtypes, such as an a1-a3 combination, is
unknown. The a1 subunit is highly and uniformly expressed in
all cortical layers, whereas the expression of the a3 subunit is
localized in layers V and VI (49). Therefore, the a1- and a3-
containing GABAA receptors should be restricted to these cor-
tical layers. Co-localization of a1 and a3 subunits has been also
observed in other discrete brain regions (such as mitral cells of
the olfactory bulb and the medial septum; Ref. 49). On the
other hand, in recombinant GABAA receptors, the co-expres-
sion of a1, a3, b2, and g2 subunits confers unique functional
properties, distinct from GABAA receptors containing a single
a subtype (50, 51). Therefore, the presence and pharmacologi-
cal activity of two different a subunit subtypes in native recep-
tor complexes, localized in discrete brain areas and/or cellular
regions, could influence the functional and pharmacological
properties of the GABAA receptor. The existence and pharma-
cological properties of a1a3-containing receptors increase the
heterogeneity of the native GABAA receptor complex in the
central nervous system.
In summary, our results demonstrate the existence of corti-
cal GABAA receptors containing both a1 and a3 subunits in
stoichiometric amounts. Furthermore, both a subunits re-
tained their benzodiazepine binding properties. However, the
a1 subunit is pharmacologically predominant over a3 subunits,
indicating the existence of active and nonactive benzodiazepine
binding sites associated with these a subunits.
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